Ixekizumab for treating axial spondyloarthritis after NSAIDs – Appraisal Consultation Document

In DRAFT guidance, NICE does not recommend ixekizumab for active ankylosing spondylitis (AS) or active non-radiographic AS with objective signs of inflammation as the estimates of cost effectiveness vs conventional therapy were above the level usually considered cost effective.

Source:

National Institute for Health and Care Excellence